Management of coccidioidomycosis in patients receiving biologic response modifiers or disease‐modifying antirheumatic drugs

Abstract

Re-treating rheumatic disease patients with a BRM and/or a DMARD after coccidioidomycosis appears to be safe in some patients. We propose a management strategy based on coccidioidomycosis disease activity.